| MeSH term | MeSH ID | Detail |
|---|---|---|
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Osteosarcoma | D012516 | 50 associated lipids |
| Glioma | D005910 | 112 associated lipids |
(e,z)-farnesol
(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol
PubChem Biomolecular Interactions and Pathways
All references with (e,z)-farnesol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Hanley K et al. | Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. | 2000 | J. Biol. Chem. | pmid:10753967 |
| Beedle AM and Zamponi GW | Block of voltage-dependent calcium channels by aliphatic monoamines. | 2000 | Biophys. J. | pmid:10866952 |
| Mussoni L et al. | Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. | 2000 | Thromb. Haemost. | pmid:10928471 |
| Mo H et al. | Farnesyl anthranilate suppresses the growth, in vitro and in vivo, of murine B16 melanomas. | 2000 | Cancer Lett. | pmid:10936674 |
| Hemmerlin A and Bach TJ | Farnesol-induced cell death and stimulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity in tobacco cv bright yellow-2 cells. | 2000 | Plant Physiol. | pmid:10938345 |
| Toró A et al. | Transannular Diels-Alder studies on the asymmetric total synthesis of chatancin: the pyranophane approach. | 2000 | Org. Lett. | pmid:10964353 |
| Eskens FA et al. | Farnesyl transferase inhibitors: current developments and future perspectives. | 2000 | Cancer Treat. Rev. | pmid:11006134 |
| Kloog Y and Cox AD | RAS inhibitors: potential for cancer therapeutics. | 2000 | Mol Med Today | pmid:11006529 |
| Bringmann A et al. | Farnesol modulates membrane currents in human retinal glial cells. | 2000 | J. Neurosci. Res. | pmid:11054809 |
| Halaschek-Wiener J et al. | A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. | 2000 | Mol. Med. | pmid:11055588 |